Patents by Inventor Peter Wipf

Peter Wipf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7858657
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: December 28, 2010
    Assignees: Proix Pharmaceutical Corp., Arizona Board of Regents, Acting on Behalf of The University of Arizona, University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Lynn D. Kirkpatrick, Garth Powis, Peter Wipf
  • Patent number: 7776908
    Abstract: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well, as tumor formation in a subject are described herein.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: August 17, 2010
    Assignees: Arizona Board of Regents, The University of Pittsburgh
    Inventors: Garth Powis, Peter Wipf
  • Patent number: 7718603
    Abstract: The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the ?-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: May 18, 2010
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina, Anthony J. Kanai
  • Publication number: 20100047841
    Abstract: Compounds of formula I, XVI and XXI possess potent cell growth inhibitory activity. These compounds are described have therapeutic utility, particularly in the treatment of cancer as well as conditions and disorders related to uncontrolled cell growth: wherein the variables R1, R2, R3, R4, R5, X, Y and Z are described herein.
    Type: Application
    Filed: February 26, 2008
    Publication date: February 25, 2010
    Inventors: Peter WIPF, Zhiyong Wang
  • Publication number: 20100035869
    Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.
    Type: Application
    Filed: July 17, 2009
    Publication date: February 11, 2010
    Inventors: Peter Wipf, Marie Coline Frantz
  • Publication number: 20090131511
    Abstract: Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer.
    Type: Application
    Filed: September 15, 2006
    Publication date: May 21, 2009
    Applicant: UNIVERSITY OF PITTSBURGH
    Inventors: Garth Powis, Peter Wipf
  • Patent number: 7528174
    Abstract: Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria dysfunction and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: May 5, 2009
    Assignee: University of Pittsburgh-Of The Commonwealth System of Higher Education
    Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina
  • Publication number: 20090087441
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Application
    Filed: September 23, 2008
    Publication date: April 2, 2009
    Applicants: Prolx Pharmaceuticals Corp., Arizona Board of Regents, acting on hehalf of The University of Arizona, The University of Pittsburgh
    Inventors: Lynn Kirkpatrick, Garth Powis, Peter Wipf
  • Publication number: 20090042808
    Abstract: Provided herein are methods for using mitochondria-targeted electron scavengers as anti-inflammatory agents. The mitochondria-targeted electron scavenger comprises a free radical-scavenging group covalently linked to a mitochondria-targeting group derived from a hemigramicidin moiety. The mitochondria-targeted electron scavenger can be used to treat medical conditions associated with acute or chronic inflammation.
    Type: Application
    Filed: August 8, 2008
    Publication date: February 12, 2009
    Inventors: Mitchell P. Fink, Peter Wipf
  • Patent number: 7446124
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: November 4, 2008
    Assignees: Prolx Pharmaceuticals Corp., The University of Pittsburgh, Arizona Board of Regents, Acting on Behalf of the University of Arizona
    Inventors: Lynn Kirkpatrick, Garth Powis, Peter Wipf
  • Publication number: 20080125479
    Abstract: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well, as tumor formation in a subject are described herein.
    Type: Application
    Filed: September 20, 2007
    Publication date: May 29, 2008
    Inventors: Garth Powis, Peter Wipf
  • Patent number: 7335679
    Abstract: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well as tumor formation in a subject are described herein.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: February 26, 2008
    Assignees: Arizona Board of Regents on behalf of the University of Arizona, University of Pittsburgh
    Inventors: Garth Powis, Peter Wipf
  • Publication number: 20070161544
    Abstract: The present invention relates to compositions and methods for providing mitochondria-selective targeting agents covalently linked to desired cargo such as radical scavenging agents. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.
    Type: Application
    Filed: August 18, 2006
    Publication date: July 12, 2007
    Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina, Anthony J. Kanai
  • Publication number: 20070161573
    Abstract: Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria dysfunction and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels.
    Type: Application
    Filed: August 17, 2006
    Publication date: July 12, 2007
    Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina
  • Patent number: 7166725
    Abstract: Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein Z1 is N or CR3; Z2 is N or CR4; Z3is O or S; A is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof; R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR5 and SO2NH2; R5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl; at least one of R1, R2, R3 and R4 is other than hydrogen; and at least one of Z1 and Z2 is other than N.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: January 23, 2007
    Assignee: Sepracor Inc.
    Inventors: Q Kevin Fang, Seth Hopkins, Michele Heffernan, Milan Chytil, Peter Wipf
  • Publication number: 20060167080
    Abstract: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well as tumor formation in a subject are described herein.
    Type: Application
    Filed: April 7, 2006
    Publication date: July 27, 2006
    Inventors: Garth Powis, Peter Wipf
  • Publication number: 20060063824
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Application
    Filed: July 11, 2005
    Publication date: March 23, 2006
    Inventors: Lynn Kirkpatrick, Garth Powis, Peter Wipf
  • Patent number: 6803475
    Abstract: A method of increasing the fluorous nature of a compound includes the step of reacting the compound with at least one second compound having the formula: wherein Rf is a fluorous group and m is 0, 1 or 2.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: October 12, 2004
    Assignee: University of Pittsburgh
    Inventors: Peter Wipf, Stephan Roever
  • Publication number: 20040082792
    Abstract: A method of increasing the fluorous nature of a compound includes the step of reacting the compound with at least one second compound having the formula: 1
    Type: Application
    Filed: October 22, 2003
    Publication date: April 29, 2004
    Inventors: Peter Wipf, Stephan Roever
  • Patent number: 6673937
    Abstract: Oxidative cyclization of bis-naphthyl ethers allows concise total syntheses of palmarumycin CP1 and deoxypreussomerin A in 8-9 steps and 15-35% overall yield from 5-hydroxy-8-methoxy-1-tetralone. A small library of palmarumycin analogs was created. Biological evaluation of these naphthoquinone spiroketals against MCF-7 and MDA-MB-231 human breast cancer cells revealed several low-micromolar growth inhibitors. A number of the analogs inhibit the thioredoxin—thioredoxin reductase system.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: January 6, 2004
    Assignee: The University of Pittsburgh
    Inventors: John S. Lazo, Peter Wipf, Billy W. Day